SEC Form 4 · accession 0001214659-19-000676
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Craig A Johnson
Director
Period of report
Jan 29, 2019
Accepted (ET)
Jan 31, 2019 · 7:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 29, 2019 | M | 7,000 | $15.79 | A | 7,000 | D | |
| Common Stock | Jan 29, 2019 | M | 10,000 | $3.65 | A | 17,000 | D | |
| Common StockF2 | Jan 29, 2019 | S | 8,475 | $61.114 | D | 8,525 | D | |
| Common StockF3 | Jan 29, 2019 | S | 8,525 | $61.7984 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)F4 | $15.79 | Jan 29, 2019 | M | 7,000 | D | — | Nov 7, 2023 | Common Stock | 7,000 | 0 | D |
| Non-Qualified Stock Option (Right to Buy)F5 | $3.65 | Jan 29, 2019 | M | 10,000 | D | — | May 16, 2027 | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2018.
- F2This transaction was executed in multiple trades at prices ranging from $60.43 to $61.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $61.44 to $62.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F41/4th of the shares subject to the Option shall vest and become exercisable on September 4, 2014, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.
- F5The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant.